Contents of Cancer Biology & Medicine in 2022（Issue 1-6）

   As a peer-reviewed open-access journal, Cancer Biology & Medicine (CBM) is published by China Anti-Cancer Association and Tianjin Medical University Cancer Institute & Hospital. It focuses on translational cancer research, dedicating to narrowing the gap between bench and bedside. CBM strictly adheres to guidelines of the International Committee of Medical Journal Editors (ICMJE), and Committee on Publication Ethics (COPE). The journal is now indexed in Science Citation Index Expanded (SCIE, IF=5.347, 5-year IF=6.624) and MEDLINE. All full texts are available in PubMed via http://www.ncbi.nlm.nih.gov/pmc/journals/2000/.

   The contents of the 1^st -6^th issue are as followed. Welcome to submit your work to CBM, which is a trusty international platform, to disseminate your research and viewpoints.

Issue 1

Editorial

Epigenetic modulation of the tumor immune microenvironment by nanoinducers to potentiate cancer immunotherapy

Ning Zhang, Xishan Hao

Cancer Biol Med. 2022 Jan 15; 19(1): 1–3. 

Reviews

Molecular testing for acute myeloid leukemia

Dahui Qin

Cancer Biol Med. 2022 Jan 15; 19(1): 4–13. 

The biogenesis, function and clinical significance of circular RNAs in breast cancer

Yan Zeng, Yutian Zou, Guanfeng Gao, Shaoquan Zheng, Song Wu, Xiaoming Xie, Hailin Tang

Cancer Biol Med. 2022 Jan 15; 19(1): 14–29.

Examining heterogeneity of stromal cells in tumor microenvironment based on pan-cancer single-cell RNA sequencing data

Wenhui Wang, Li Wang, Junjun She, Jun Zhu

Cancer Biol Med. 2022 Jan 15; 19(1): 30–42. 

Commensal microbiota in the digestive tract: a review of its roles in carcinogenesis and radiotherapy

Jiali Dong, Yuan Li, Huiwen Xiao, Ming Cui, Saijun Fan

Cancer Biol Med. 2022 Jan 15; 19(1): 43–55. 

Original Articles

Single-cell trajectories of melanoma cell resistance to targeted treatment

Maria Schmidt, Lena Sünke Mortensen, Henry Loeffler-Wirth, Corinna Kosnopfel, Knut Krohn, Hans Binder, Manfred Kunz

Cancer Biol Med. 2022 Jan 15; 19(1): 56–73. 

Drug repurposing for cancer treatment through global propagation with a greedy algorithm in a multilayer network

Xi Cheng, Wensi Zhao, Mengdi Zhu, Bo Wang, Xuege Wang, Xiaoyun Yang, Yuqi Huang, Minjia Tan, Jing Li

Cancer Biol Med. 2022 Jan 15; 19(1): 74–89. 

Protein convertase subtilisin/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway

Mingyan He, Jing Hu, Tingting Fang, Wenqing Tang, Bei Lv, Biwei Yang, Jinglin Xia

Cancer Biol Med. 2022 Jan 15; 19(1): 90–103. 

SNORA23 inhibits HCC tumorigenesis by impairing the 2′-O-ribose methylation level of 28S rRNA

Zhiyong Liu, Yanan Pang, Yin Jia, Qin Qin, Rui Wang, Wei Li, Jie Jing, Haidong Liu, Shanrong Liu

Cancer Biol Med. 2022 Jan 15; 19(1): 104–119.

CUL4B facilitates HBV replication by promoting HBx stabilization

Haixia Shan, Bo Wang, Xiaodong Zhang, Hui Song, Xi Li, Yongxin Zou, Baichun Jiang, Huili Hu, Hao Dou, Changshun Shao, Lifen Gao, Chunhong Ma, Xiaoyun Yang, Xiaohong Liang, Yaoqin Gong

Cancer Biol Med. 2022 Jan 15; 19(1): 120–131. 

Issue 2

Editorials

Highlighted multi-modifications of enzymes: a novel succinylation mediated by histone acetyltransferase 1 in tumors

Xiaodong Zhang, Chunyu Hou, Guang Yang

Cancer Biol Med. 2022 Feb 15; 19(2): 133–135. 

A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer

Yuchen Guo, Yangyang Zhou, Wenxin Qin

Cancer Biol Med. 2022 Feb 15; 19(2): 136–139.

The emerging role of long noncoding RNA RMRP in cancer development and targeted therapy

Qian Hao, Xiang Zhou

Cancer Biol Med. 2022 Feb 15; 19(2): 140–146.

Reviews

Tumorigenic bacteria in colorectal cancer: mechanisms and treatments

Sha Li, Jinyi Liu, Xiangjin Zheng, Liwen Ren, Yihui Yang, Wan Li, Weiqi Fu, Jinhua Wang, Guanhua Du

Cancer Biol Med. 2022 Feb 15; 19(2): 147–162. 

Cancer metabolism and dietary interventions

Lin Qian, Fan Zhang, Miao Yin, Qunying Lei

Cancer Biol Med. 2022 Feb 15; 19(2): 163–174.

Global pattern and trends of colorectal cancer survival: a systematic review of population-based registration data

Yufei Jiang, Huiyun Yuan, Zhuoying Li, Xiaowei Ji, Qiuming Shen, Jiayi Tuo, Jinghao Bi, Honglan Li, Yongbing Xiang

Cancer Biol Med. 2022 Feb 15; 19(2): 175–186. 

The advance of adjuvant treatment for triple-negative breast cancer

Jingyu Ge, Wenjia Zuo, Yiyu Chen, Zhiming Shao, Keda Yu

Cancer Biol Med. 2022 Feb 15; 19(2): 187–201.

Updates in endocrine therapy for metastatic breast cancer

Poorni M. Manohar, Nancy E. Davidson

Cancer Biol Med. 2022 Feb 15; 19(2): 202–212. 

Original Articles

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer

Xinyi Zhou, Qian Xiao, Dongliang Fu, Haochen Zhang, Yang Tang, Jinjie He, Yeting Hu, Xiangxing Kong, Fei Teng, Xiangrui Liu, Ying Yuan, Kefeng Ding

Cancer Biol Med. 2022 Feb 15; 19(2): 213–228.

Systematic screening reveals synergistic interactions that overcome MAPK inhibitor resistance in cancer cells

Yu Yu, Minzhen Tao, Libin Xu, Lei Cao, Baoyu Le, Na An, Jilin Dong, Yajie Xu, Baoxing Yang, Wei Li, Bing Liu, Qiong Wu, Yinying Lu, Zhen Xie, Xiaohua Lian

Cancer Biol Med. 2022 Feb 15; 19(2): 229–252.

Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women

Fenfen Fu, Dongjie Zhang, Li Hu, Senthil Sundaram, Dingge Ying, Ying Zhang, Shuna Fu, Juan Zhang, Lu Yao, Ye Xu, Yuntao Xie

Cancer Biol Med. 2022 Feb 15; 19(2): 253–262. 

Erratum

Erratum to A truncated protein product of the germline variant of the DUOX2 gene leads to adenomatous polyposis

Mengyuan Yang, Yingxin Zhao, Yuwei Ding, Juan Wang, Yinuo Tan, Dong Xu, Ying Yuan

Cancer Biol Med. 2022 Feb 15; 19(2): 263. 

Issue 3

Editorial

Decoding the intercellular communication network during tumorigenesis

Liwei An, Ruixian Yu, Yi Han, Zhaocai Zhou

Cancer Biol Med. 2022 Mar 15; 19(3): 265–272. Published online 2021 Nov 17. doi: 10.20892/j.issn.2095-3941.2021.0558

Deep proteome profiling promotes whole proteome characterization and drug discovery for esophageal squamous cell carcinoma

Wei Liu, Yongping Cui, Wen Liu, Zhihua Liu, Liyan Xu, Enmin Li

Cancer Biol Med. 2022 Mar 15; 19(3): 273–277. Published online 2022 Mar 14. doi: 10.20892/j.issn.2095-3941.2022.0024

Perspective

Perspective on novel proteins encoded by circular RNAs in glioblastoma

Xixi Li, Xinya Gao, Nu Zhang

Cancer Biol Med. 2022 Mar 15; 19(3): 278–283. Published online 2022 Feb 14. doi: 10.20892/j.issn.2095-3941.2021.0678

Decoding the complexity of metastasis

Yingcheng Wu, Tiancheng Zhang, Xiaoming Zhang, Qiang Gao

Cancer Biol Med. 2022 Mar 15; 19(3): 284–288. Published online 2022 Mar 14. doi: 10.20892/j.issn.2095-3941.2022.0031

Reviews

Modulating microRNAs in cancer: next-generation therapies

Nahid Arghiani, Khalid Shah

Cancer Biol Med. 2022 Mar 15; 19(3): 289–304. Published online 2021 Dec 1. doi: 10.20892/j.issn.2095-3941.2021.0294

The Wnt/β-catenin signaling pathway in the tumor microenvironment of hepatocellular carcinoma

Kaiting Wang, Xinyao Qiu, Yan Zhao, Hongyang Wang, Lei Chen

Cancer Biol Med. 2022 Mar 15; 19(3): 305–318. Published online 2021 Oct 12. doi: 10.20892/j.issn.2095-3941.2021.0306

Tumor organoids for cancer research and personalized medicine

Hui Yang, Yinuo Wang, Peng Wang, Ning Zhang, Pengyuan Wang

Cancer Biol Med. 2022 Mar 15; 19(3): 319–332. Published online 2021 Sep 14. doi: 10.20892/j.issn.2095-3941.2021.0335

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome

Hanfei Guo, Lei Qian, Jiuwei Cui

Cancer Biol Med. 2022 Mar 15; 19(3): 333–342. Published online 2021 Sep 28. doi: 10.20892/j.issn.2095-3941.2021.0087

Original Article

The m6A writers regulated by the IL-6/STAT3 inflammatory pathway facilitate cancer cell stemness in cholangiocarcinoma

Hua Ye, Tianqi Chen, Zhancheng Zeng, Bo He, Qianqian Yang, Qi Pan, Yueqin Chen, Wentao Wang

Cancer Biol Med. 2022 Mar 15; 19(3): 343–357. Published online 2021 Aug 4. doi: 10.20892/j.issn.2095-3941.2020.0661

Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma

Ming Bai, Meng Wang, Ting Deng, Yuxian Bai, Kai Zang, Zhanhui Miao, Wenlin Gai, Liangzhi Xie, Yi Ba

Cancer Biol Med. 2022 Mar 15; 19(3): 358–369. Published online 2022 Jan 12. doi: 10.20892/j.issn.2095-3941.2021.0388

Dietary fat intake and liver cancer risk: A prospective cohort study in Chinese women

Xiaowei Ji, Jing Wang, Zhuoying Li, Qiuming Shen, Jiayi Tuo, Jinghao Bi, Yuting Tan, Honglan Li, Yongbing Xiang

Cancer Biol Med. 2022 Mar 15; 19(3): 370–383. Published online 2021 Sep 21. doi: 10.20892/j.issn.2095-3941.2020.0633

Issue 4

Reviews

N⁶-methyladenosine (m⁶A) RNA modification in tumor immunity

Siyi Zheng, Hui Han and Shuibin Lin

Cancer Biology & Medicine April 2022, 19 (4) 385-397; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0534

Methods for monitoring cancer cell pyroptosis

Shuo Wang, Yuantong Liu, Lu Zhang and Zhijun Sun

Cancer Biology & Medicine April 2022, 19 (4) 398-414; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0504

Research progress in hepatitis B virus covalently closed circular DNA

Xiaodong Zhang, Yufei Wang and Guang Yang

Cancer Biology & Medicine April 2022, 19 (4) 415-431; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0454

Effects of menopausal hormone therapy-based on the role of estrogens, progestogens, and their metabolites in proliferation of breast cancer cells

Yu Deng and Hongyan Jin

Cancer Biology & Medicine April 2022, 19 (4) 432-449; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0344

Breast cancer screening and early diagnosis in Chinese women

Rui Ding, Yi Xiao, Miao Mo, Ying Zheng, Yi-Zhou Jiang and Zhi-Ming Shao

Cancer Biology & Medicine April 2022, 19 (4) 450-467; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0676

Original Articles

SHP-1 acts as a tumor suppressor by interacting with EGFR and predicts the prognosis of human breast cancer

Qian Geng, Ruiting Xian, Yinjue Yu, Fengsheng Chen and Rong Li

Cancer Biology & Medicine April 2022, 19 (4) 468-485; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0501

PGK1-coupled HSP90 stabilizes GSK3β expression to regulate the stemness of breast cancer stem cells

Wei Tang, Yu Wu, Xin Qi, Rilei Yu, Zhimin Lu, Ao Chen, Xinglong Fan and Jing Li

Cancer Biology & Medicine April 2022, 19 (4) 486-503; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0362

Overexpressed NEDD8 as a potential therapeutic target in esophageal squamous cell carcinoma

Jingrong Xian, Shiwen Wang, Yanyu Jiang, Lihui Li, Lili Cai, Ping Chen, Yue Liu, Xiaofei Zeng, Guoan Chen, Chen Ding, Robert M. Hoffman, Lijun Jia, Hu Zhao and Yanmei Zhang

Cancer Biology & Medicine April 2022, 19 (4) 504-517; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0484

Is adjuvant chemotherapy necessary for early gastric cancer?

Yu Mei, Tienan Feng, Min Yan, Zhenggang Zhu and Zhenglun Zhu

Cancer Biology & Medicine April 2022, 19 (4) 518-532; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0636

Comparative profiling of immune genes improves the prognoses of lower grade gliomas

Zhiliang Wang, Wen Cheng, Zheng Zhao, Zheng Wang, Chuanbao Zhang, Guanzhang Li, Anhua Wu and Tao Jiang

Cancer Biology & Medicine April 2022, 19 (4) 533-550; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0173

Prognostic significance of a combined and controlled nutritional status score and EBV-DNA in patients with advanced nasopharyngeal carcinoma: a long-term follow-up study

Hui Lu, Shanshan Guo, Liting Liu, Qiuyan Chen, Yujing Liang, Sailan Liu, Xuesong Sun, Qingnan Tang, Xiaoyun Li, Ling Guo, Haoyuan Mo, Linquan Tang and Haiqiang Mai

Cancer Biology & Medicine April 2022, 19 (4) 551-564; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0627

Issue 5

Editorial

PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer

Han Liang

Cancer Biol Med. 2022 May 15; 19(5): 565–568. Published online 2022 Jun 9. doi: 10.20892/j.issn.2095-3941.2022.0244

Perspective

Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era

Jiakang Li, Jingyan Xu, Mingyi Yang, Qing Zhou

Cancer Biol Med. 2022 May 15; 19(5): 569–572. Published online 2022 Jun 9. doi: 10.20892/j.issn.2095-3941.2022.0254

Reviews

Targeting the COP9 signalosome for cancer therapy

Wenqi Du, Ruicheng Zhang, Bilal Muhammad, Dongsheng Pei

Cancer Biol Med. 2022 May 15; 19(5): 573–590. Published online 2022 Mar 21. doi: 10.20892/j.issn.2095-3941.2021.0605

Advances in lung cancer screening and early detection

Caichen Li, Huiting Wang, Yu Jiang, Wenhai Fu, Xiwen Liu, Ran Zhong, Bo Cheng, Feng Zhu, Yang Xiang, Jianxing He, Wenhua Liang

Cancer Biol Med. 2022 May 15; 19(5): 591–608. Published online 2022 May 11. doi: 10.20892/j.issn.2095-3941.2021.0690

Immunology and immunotherapy in breast cancer

Vladimir Semiglazov, Andrey Tseluiko, Asel Kudaybergenova, Anna Artemyeva, Petr Krivorotko, Roman Donskih

Cancer Biol Med. 2022 May 15; 19(5): 609–618. Published online 2022 Jun 9. doi: 10.20892/j.issn.2095-3941.2021.0597

The active surveillance management approach for patients with low risk papillary thyroid microcarcinomas: is China ready?

Wen Liu, Xuejing Yan, Ruochuan Cheng

Cancer Biol Med. 2022 May 15; 19(5): 619–634. Published online 2021 Sep 24. doi: 10.20892/j.issn.2095-3941.2021.0058

Original Articles

Akt isoforms differentially provide for chemoresistance in prostate cancer

Bo Ma, Hanshuang Shao, Xia Jiang, Zhou Wang, Chuanyue (Cary) Wu, Diana Whaley, Alan Wells

Cancer Biol Med. 2022 May 15; 19(5): 635–650. Published online 2021 Oct 1. doi: 10.20892/j.issn.2095-3941.2020.0747

JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKKβ

Zilu Zhang, Chenjing Ye, Jia Liu, Wenbin Xu, Chao Wu, Qing Yu, Xiaoguang Xu, Xinyi Zeng, Huizi Jin, Yingli Wu, Hua Yan

Cancer Biol Med. 2022 May 15; 19(5): 651–668. Published online 2021 Sep 28. doi: 10.20892/j.issn.2095-3941.2020.0473

Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion via integrin/BRAF/TAK1/ERK/ETV4 signaling

Panpan Ma, Xinxin Jin, Zhiwei Fan, Zhou Wang, Suhui Yue, Changyue Wu, Shiyin Chen, Yuanyuan Wu, Miaomiao Chen, Donghua Gu, Siliang Zhang, Renfang Mao, Yihui Fan

Cancer Biol Med. 2022 May 15; 19(5): 669–684. Published online 2021 Oct 9. doi: 10.20892/j.issn.2095-3941.2021.0137

Somatic copy number alterations are predictive of progression-free survival in patients with lung adenocarcinoma undergoing radiotherapy

Fan Kou, Lei Wu, Yan Guo, Bailu Zhang, Baihui Li, Ziqi Huang, Xiubao Ren, Lili Yang

Cancer Biol Med. 2022 May 15; 19(5): 685–695. Published online 2021 Aug 27. doi: 10.20892/j.issn.2095-3941.2020.0728

Effects of population aging on the mortality burden of related cancers in urban and rural areas of China, 2004–2017: a population-based study

Yali Chen, Cuihong Yang, Ning Li, Zixing Wang, Peng Wu, Jin Du, Jingmei Jiang

Cancer Biol Med. 2022 May 15; 19(5): 696–706. Published online 2022 Mar 2. doi: 10.20892/j.issn.2095-3941.2021.0538

Comprehensive characterization of CRC with germline mutations reveals a distinct somatic mutational landscape and elevated cancer risk in the Chinese population

Jianfei Yao, Yunhuan Zhen, Jing Fan, Yuan Gong, Yumeng Ye, Shaohua Guo, Hongyi Liu, Xiaoyun Li, Guosheng Li, Pan Yang, Xiaohui Wang, Danni Liu, Tanxiao Huang, Huiya Cao, Peisu Suo, Yuemin Li, Jingbo Yu, Lele Song

Cancer Biol Med. 2022 May 15; 19(5): 707–732. Published online 2022 Jan 12. doi: 10.20892/j.issn.2095-3941.2021.0190

Improved diagnosis of thyroid cancer aided with deep learning applied to sonographic text reports: a retrospective, multi-cohort, diagnostic study

Qiang Zhang, Sheng Zhang, Jianxin Li, Yi Pan, Jing Zhao, Yixing Feng, Yanhui Zhao, Xiaoqing Wang, Zhiming Zheng, Xiangming Yang, Lixia Liu, Chunxin Qin, Ke Zhao, Xiaonan Liu, Caixia Li, Liuyang Zhang, Chunrui Yang, Na Zhuo, Hong Zhang, Jie Liu, Jinglei Gao, Xiaoling Di, Fanbo Meng, Wei Ji, Meng Yang, Xiaojie Xin, Xi Wei, Rui Jin, Lun Zhang, Xudong Wang, Fengju Song, Xiangqian Zheng, Ming Gao, Kexin Chen, Xiangchun Li

Cancer Biol Med. 2022 May 15; 19(5): 733–741. Published online 2021 Sep 7. doi: 10.20892/j.issn.2095-3941.2020.0509

Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis

Junjie Li, Li Chen, Wei Tan, Fang Qi, Yang Zhang, Zhonghua Wang, Zhimin Shao

Cancer Biol Med. 2022 May 15; 19(5): 742–754. Published online 2022 Feb 16. doi: 10.20892/j.issn.2095-3941.2021.0529

The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study

Litong Yao, Zhiyuan Pang, Mozhi Wang, Mengshen Wang, Xiangyu Sun, Mingke Cui, Yanfu Zheng, Xinyan Li, Haoran Dong, Qiang Zhang, Yingying Xu

Cancer Biol Med. 2022 May 15; 19(5): 755–767. Published online 2021 Oct 12. doi: 10.20892/j.issn.2095-3941.2020.0800

Issue 6

Editorial

 Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification

Jianbin Li, Zefei Jiang

Cancer Biol Med. 2022 Jun 15; 19(6): 769–773. Published online 2022 Jun 29. doi: 10.20892/j.issn.2095-3941.2022.0277

Reviews

 Anti-tumor pharmacology of natural products targeting mitosis

Manru Huang, Caiyan Liu, Yingying Shao, Shiyue Zhou, Gaoyong Hu, Shuangshuang Yin, Weiling Pu, Haiyang Yu

Cancer Biol Med. 2022 Jun 15; 19(6): 774–801. Published online 2022 Jun 15. doi: 10.20892/j.issn.2095-3941.2022.0006

The advanced development of molecular targeted therapy for hepatocellular carcinoma

Tao Yan, Lingxiang Yu, Ning Zhang, Caiyun Peng, Guodong Su, Yi Jing, Linzhi Zhang, Tong Wu, Jiamin Cheng, Qian Guo, Xiaoliang Shi, Yinying Lu

Cancer Biol Med. 2022 Jun 15; 19(6): 802–817. Published online 2022 Jun 15. doi: 10.20892/j.issn.2095-3941.2021.0661

Original Articles

MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis

Fengqi Yan, Qinhao Wang, Mingyuan Xia, Yi Ru, Wei Hu, Guang Yan, Xin Xiong, Mei Zhang, Jiancai Wang, Qi Li, Bo Zhang, He Wang, Wei Lin, Guojun Wu, Xia Li

Cancer Biol Med. 2022 Jun 15; 19(6): 818–835. Published online 2021 Dec 22. doi: 10.20892/j.issn.2095-3941.2020.0296

EHMT2 (G9a) activation in mantle cell lymphoma and its associated DNA methylation and gene expression

Jun Wang, Hui Xu, Shuang Ge, Chaoshuai Xue, Hailing Li, Xiaotong Jing, Ke Liang, Xiaoying Zhang, Cuijuan Zhang

Cancer Biol Med. 2022 Jun 15; 19(6): 836–849. Published online 2021 Oct 12. doi: 10.20892/j.issn.2095-3941.2020.0371

The mutation landscape of multiple cancer predisposition genes in Chinese familial/hereditary breast cancer families

Li Dong, Hailian Zhang, Huan Zhang, Yingnan Ye, Yanan Cheng, Lijuan Li, Lijuan Wei, Lei Han, Yandong Cao, Shixia Li, Xishan Hao, Juntian Liu, Jinpu Yu

Cancer Biol Med. 2022 Jun 15; 19(6): 850–870. Published online 2021 Sep 28. doi: 10.20892/j.issn.2095-3941.2021.0011

Treatment patterns and a prognostic scoring system for elderly acute myeloid leukemia patients: a retrospective multicenter cohort study in China

Chunli Zhang, Wei Wan, Shuai Zhang, Jingwen Wang, Ru Feng, Jiangtao Li, Junyue Chai, Hebing Zhou, Liru Wang, Yuping Zhong, Xiaodong Mo, Mengzhu Shen, Hongmei Jing, Hui Liu

Cancer Biol Med. 2022 Jun 15; 19(6): 871–883. Published online 2021 Aug 27. doi: 10.20892/j.issn.2095-3941.2020.0474

Microsurgery vs. radiosurgery for the treatment of multiple metastases in the brain: a retrospective cohort study

Qun Liu, Qiang Yin, Yang Dong, Fengtong Li, Wenliang Li, Xiaoguang Wang

Cancer Biol Med. 2022 Jun 15; 19(6): 884–892. Published online 2021 Sep 8. doi: 10.20892/j.issn.2095-3941.2020.0598

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP

Yan Qin, Haizhu Chen, Peng Liu, Changgong Zhang, Jianliang Yang, Lin Gui, Xiaohui He, Liqiang Zhou, Shengyu Zhou, Shiyu Jiang, Hongxin Jiang, Yuankai Shi

Cancer Biol Med. 2022 Jun 15; 19(6): 893–909. Published online 2021 Nov 23. doi: 10.20892/j.issn.2095-3941.2021.0193

The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma

Jia Lu, Ting Li, Zhichao Liao, Hui Yu, Yongtian Zhao, Haixiao Wu, Zhiwu Ren, Jun Zhao, Ruwei Xing, Sheng Teng, Yun Yang, Xiangchun Li, Kexin Chen, Jonathan Trent, Jilong Yang

Cancer Biol Med. 2022 Jun 15; 19(6): 910–930. Published online 2021 Nov 25. doi: 10.20892/j.issn.2095-3941.2021.0270

Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04)

Sung Uk Lee, Jinsil Seong, Tae Hyun Kim, Jung Ho Im, Woo Chul Kim, Kyubo Kim, Hae Jin Park, Tae Gyu Kim, Youngkyong Kim, Bae Kwon Jeong, Jin Hee Kim, Byoung Hyuck Kim, Taek-Keun Nam

Cancer Biol Med. 2022 Jun 15; 19(6): 931–944. Published online 2021 Dec 20. doi: 10.20892/j.issn.2095-3941.2020.0667